左乙拉西坦对阿尔茨海默病伴或不伴癫痫样活动患者认知的影响:一项随机临床试验
这项2a期随机双盲安慰剂对照交叉试验纳入34例阿尔茨海默病成人患者,评估左乙拉西坦改善认知的能力。总体而言,左乙拉西坦未改变主要结局NIH-EXAMINER复合评分,但在预设分析中,伴癫痫样活动的患者接受左乙拉西坦后Stroop干扰命名和虚拟路线学习测试表现改善。
要点
- 左乙拉西坦未改善AD患者总体执行功能复合评分。
- 伴癫痫样活动的AD患者空间记忆和执行功能任务有改善。
- 左乙拉西坦耐受性良好,无因不良事件停药。
核心结论
- 左乙拉西坦总体未改善AD患者主要认知结局,但在伴癫痫样活动者中预设分析显示空间记忆和执行功能任务改善。
研究设计与样本
- LEV-AD研究为2a期随机双盲安慰剂对照交叉临床试验,纳入34例AD成人,在加州大学旧金山分校和明尼苏达大学双子城校区于2014年10月16日至2020年7月21日进行。
主要发现
- 无因不良事件导致的治疗中止。
关键数值与推荐
- 纳入标准为年龄80岁及以下,简易精神状态检查评分≥18分和/或临床痴呆评定量表评分<2分。
- 左乙拉西坦口服125mg每日两次,每阶段4周,洗脱期4周。
临床怎么用
- 对于伴癫痫样活动的AD患者,左乙拉西坦可能改善空间记忆和执行功能任务表现,但总体认知改善证据不足。
局限性
- 样本量较小(34例),研究为2a期探索性试验,伴癫痫样活动亚组分析为预设但 exploratory。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Network hyperexcitability may contribute to cognitive dysfunction in patients with Alzheimer disease (AD). OBJECTIVE: To determine the ability of the antiseizure drug levetiracetam to improve cognition in persons with AD. DESIGN, SETTING, AND PARTICIPANTS: The Levetiracetam for Alzheimer's Disease-Associated Network Hyperexcitability (LEV-AD) study was a phase 2a randomized double-blinded placebo-controlled crossover clinical trial of 34 adults with AD that was conducted at the University of California, San Francisco, and the University of Minnesota, Twin Cities, between October 16, 2014, and July 21, 2020. Participants were adults 80 years and younger who had a Mini-Mental State Examination score of 18 points or higher and/or a Clinical Dementia Rating score of less than 2 points. Screening included overnight video electroencephalography and a 1-hour resting magnetoencephalography examination. INTERVENTIONS: Group A received placebo twice daily for 4 weeks followed by a 4-week washout period, then oral levetiracetam, 125 mg, twice daily for 4 weeks. Group B received treatment using the reverse sequence. MAIN OUTCOMES AND MEASURES: The primary outcome was the ability of levetiracetam treatment to improve executive function (measured by the National Institutes of Health Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research [NIH-EXAMINER] composite score). Secondary outcomes were cognition (measured by the Stroop Color and Word Test [Stroop] interference naming subscale and the Alzheimer's Disease Assessment Scale-Cognitive Subscale) and disability. Exploratory outcomes included performance on a virtual route learning test and scores on cognitive and functional tests among participants with epileptiform activity. RESULTS: Of 54 adults assessed for eligibility, 11 did not meet study criteria, and 9 declined to participate. A total of 34 adults (21 women [61.8%]; mean [SD] age, 62.3 [7.7] years) with AD were enrolled and randomized (17 participants to group A and 17 participants to group B). Thirteen participants (38.2%) were categorized as having epileptiform activity. In total, 28 participants (82.4%) completed the study, 10 of whom (35.7%) had epileptiform activity. Overall, treatment with levetiracetam did not change NIH-EXAMINER composite scores (mean difference vs placebo, 0.07 points; 95% CI, -0.18 to 0.32 points; P = .55) or secondary measures. However, among participants with epileptiform activity, levetiracetam treatment improved performance on the Stroop interference naming subscale (net improvement vs placebo, 7.4 points; 95% CI, 0.2-14.7 points; P = .046) and the virtual route learning test (t = 2.36; Cohen f2 = 0.11; P = .02). There were no treatment discontinuations because of adverse events. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, levetiracetam was well tolerated and, although it did not improve the primary outcome, in prespecified analysis, levetiracetam improved performance on spatial memory and executive function tasks in patients with AD and epileptiform activity. These exploratory findings warrant further assessment of antiseizure approaches in AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02002819.
引用
- Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial. JAMA Neurol. 2021. PMID: 34570177. doi:10.1001/jamaneurol.2021.3310
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。